Pharmacogenomics: current status and future perspectives
M Pirmohamed - Nature Reviews Genetics, 2023 - nature.com
Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …
become an increasing problem globally given the growing elderly population requiring …
[HTML][HTML] Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
P Sharma, JP Allison - Cell, 2015 - cell.com
Research in two fronts has enabled the development of therapies that provide significant
benefit to cancer patients. One area stems from a detailed knowledge of mutations that …
benefit to cancer patients. One area stems from a detailed knowledge of mutations that …
[HTML][HTML] ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero… - Annals of …, 2016 - Elsevier
Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
C Robert, GV Long, B Brady, C Dutriaux… - New England journal …, 2015 - Mass Medical Soc
Background Nivolumab was associated with higher rates of objective response than
chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic …
chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic …
Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in melanoma
H Lv, X Liu, X Zeng, Y Liu, C Zhang… - Frontiers in …, 2022 - frontiersin.org
Skin cutaneous melanoma (SKCM, hereafter referred to as melanoma) is the most lethal
skin cancer with increasing incidence. Regulated cell death plays an important role in …
skin cancer with increasing incidence. Regulated cell death plays an important role in …
A comprehensive review on MAPK: a promising therapeutic target in cancer
The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch
from extracellular signals to intracellular responses. Alterations of signaling cascades are …
from extracellular signals to intracellular responses. Alterations of signaling cascades are …
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Background Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall
and progression-free survival of pembrolizumab versus ipilimumab in patients with …
and progression-free survival of pembrolizumab versus ipilimumab in patients with …
[HTML][HTML] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott… - Journal of clinical …, 2014 - ascopubs.org
Purpose Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T
cells that downmodulates effector functions and limits the generation of immune memory. PD …
cells that downmodulates effector functions and limits the generation of immune memory. PD …
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …
delays the emergence of resistance and reduces toxic effects in patients who have …